Hostname: page-component-7b7567c8c-jswmv Total loading time: 0 Render date: 2026-11-15T14:49:17.539Z Has data issue: false hasContentIssue false
  • English
  • Français

Hepatitis B Immunoprophylaxis: Developing a Cost-Effective Program in the Hospital Setting

Published online by Cambridge University Press:  21 June 2016

Bruce P. Lanphear
Bruce P. Lanphear*
Affiliation:
Medical Center Health Services, University of Cincinnati, Cincinnati, Ohio
*
Medical Center Heath Services, Mail Location #705, University of Cincinnati, Cincinnati, OH 45267
Get accessRights & Permissions [Opens in a new window]

Extract

There are several goals of a hepatitis B immunoprophylaxis program. Prevention of clinical disease and carrier status in healthcare workers (HCW) is the primary goal. In addition, the uncommon incidence of staff transmitting hepatitis B infection (HBV) to patients should not continue with available methods of prevention. The prevention of disease is not only desirable from a public health standpoint, it is also needed to protect health centers from liability that may result from the occurrence of preventable diseases of occupational origin, such as HBV.

Information

Type
Readers' Forum
Information
Infection Control & Hospital Epidemiology , Volume 11 , Issue 1 , January 1990, pp. 47 - 50
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1990 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1. Mulley, AG, Silverstein, MD, Dienstag, JL. Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. New Engl J Med. 1982;307:644–652.Google Scholar
2. Welch, J, Webster, M, Tilzey, AJ, Noah, ND, Banatvala, JE. Hepatitis B infections after gynecologic surgery. Lancets. 1989; 205–206.Google Scholar
3. Lettau, LA, Smith, JD, Williams, D, et al. Transmission of hepatitis B with resultant restriction of surgical practice. JAMA. 1986;255:934–937.Google Scholar
4. Baker, CH, Brennan, JM. Keeping health-care workers healthy: legal aspects of hepatitis B immunization programs. New Engl J Med. 1984;311:684–688.Google Scholar
5. Centers for Disease Control. Changing patterns of groups at high risk for hepatitis B in the United States. MMWR. 1988;37;429–432.Google Scholar
6. Department of Labor/Department of Health and Human Services. Protection against occupational exposure to hepatitis B virus and the human immunodeficiency virus. Washington, DC: US Government Printing Office; October 1987:1–14.Google Scholar
7. Centers for Disease Control. Update on hepatitis B prevention. MMWR. 1987;36:353–360.Google Scholar
8. Hashimoto, F, Hunt, WC, Brusuelas, H Physician acceptance of the hepatitis B vaccine at a university medical center. Am J Public Health. 1988;78:973–974.Google Scholar
9. Grady, GF, Lee, VA, Prince, AM, et al. hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multi-center controlled trial. J Infect Dis. 1978;138:625–638.Google Scholar
10. Seeff, LB, Wright, EC, Zimmerman, HJ et al. Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Ann Internal Med. 1978;88:285–293.Google Scholar
11. Krugman, S, Gilles, JP, Hammond, J. Viral hepatitis, type B (MS-2 strain: studies on active immunization. JAMA. 1971;217:41–45.Google Scholar
12. Szmuness, W, Stevens, CE, Harley, EJ, et al. hepatitis B vaccine in medical staff of hemodialysis units; efficacy and sub-type cross protection. New Engl J Med. 1982;307:1481–1486.Google Scholar
13. Francis, DP, Hadler, SC, Thompson, SE, et al. The prevention of hepatitis B with vaccine. Ann Intern Med. 1982;97:362–366.Google Scholar
14. Szmuness, W, Stevens, CE, Zang, EA, Harley, EJ Kellner, A. A controlled clinical trial of the efficacy of the Hepatitis B vaccine (Heptavax B); A final report. Hepatology. 1981;1:377–385.Google Scholar
15. Centers for Disease Control. Recommendations for protection against viral hepatitis. MMWR. 1985;34: 313–324, 329–335.Google Scholar
16. Linnemann, CC Jr, Hegg, ME, Ramundo, N, Schiff, GN. Screening hospital patients for Hepatitis B surface antigen. Am J Clin Pathol. 1977;67:257–259.Google Scholar
17. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, Hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988;37:377–382, 387–388.Google Scholar
18. Hadler, S, Francis, DP, Maynard, JE et al. Long term immunogenicity and efficacy of Hepatitis B vaccine in homosexual men. New Engl J Med. 1986;315:209–214.Google Scholar
19. Taylor, PE, Stevens, CE. Persistence of antibody to Hepatitis B surface antigen after vaccination with Hepatitis B vaccine. [Abstract]J Med Virol. 1987;21:90–A.Google Scholar
20. Hadler, S. Are booster doses of hepatitis B vaccine necessary? (ed)Ann Intern Med. 1988;108:457–458.Google Scholar
21. Wainwright, RB, McMahon, BJ, Bulkow, LR, et al. Duration of immunogenicity and efficacy of Hepatitis B vaccine in a Yupik eskimo population. JAMA. 1989;261:2362–2366.Google Scholar
22. Immunization against hepatitis B. Lancet. 1988; 875–876.Google Scholar
23. Davidson, M, Krugman, S. Recombinant yeast Hepatitis B vaccine compared with plasma-derived vaccine: immunogenicity and effect of a booster dose. J Infect. 1986;13:(suppl A)31–38.Google Scholar
24. Hepatitis B panel. Discussion. J Infect. 1986; 13(suppl A):73–78.Google Scholar
25. McLean, AA, Hilleman, MR, McAleer, WJ, Bunyak, EB. Summary of worldwide clinical experience with H-B-Vax. J Infect. 1983;7(suppl):95–104.Google Scholar
26. Barnas, GP, Hanacik, LJ. Hepatitis B vaccine: persistence of antibody following immunization. Infect Control Hosp Epidemiol. 1988;9:147–150.Google Scholar
27. Horowitz, MM, Ershler, WB, McKinney, WP, Battiola, RJ. Duration of immunity after Hepatitis B vaccination: efficacy of low-dose booster vaccine. Ann Intern Med. 1988;108:185–189.Google Scholar
28. Jilg, W, Schmidt, M, Deinhardt, F. Persistence of specific antibodies after Hepatitis B vaccination. J Hepatol. 1988;6:201–207.Google Scholar
29. Haas, R, Beidman, ME. Marketing a Hepatitis B vaccine program. Infect Control. 1986;7:339–341.Google Scholar
30. Zajac, BA, West, DJ, McAleer, WJ. Scolnick, EM. Overview of clinical studies with Hepatitis B vaccine made by recombinant DNA. J Infect. 1986;13(suppl A):39–45.Google Scholar
31. Dandalos, E, Roumeliotou-Karayannis, A, Richardson, SC, Papaevangelou, G. Safety and immunogenicity of a recombinant Hepatitis B vaccine. J Med Virol. 1985;17:57–62.Google Scholar
32. Tong, MJ, Co, RL, Marci, RD, Michaelson, PM, Ortega, G. A cost comparison analysis for screening and vaccination of hospital personnel with high and low prevalence Hepatitis B virus antibodies in California. Infect Control Hosp Epidemiol. 1988;9(2):66–71.Google Scholar